90-day Pod-type Etonogestrel/Ethinyl Estradiol/QGriffithsin (QGRFT) Intravaginal Ring [EEQ IVR]
A 90-day pod-type MPT IVR for pregnancy and HIV prevention that could reduce both the emergence of ARV-resistant HIV and the concern of potential increased risk of HIV transmission associated with use of progestin-only products.
Preclinical – Early (Pre1)
Delivery Route & Method:
Topical - Intravaginal Ring (IVR)
Mechanism of Action:
Ovulation inhibition (pregnancy); binding to HIV envelope glycoproteins to prevent entry of HIV into target cells (QGRFT).
- Oak Crest Institute of Science
- Population Council
- Nat. Institute Allergy & Infect. Diseases (NIAID)
- National Institutes of Health (NIH)
NIH: R01 (NIAID)
- Ethinyl Estradiol
- QGriffithsin (QGRFT)